Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.

Abstract

In an open-label, randomized, crossover study 12 healthy volunteers were given clarithromycin orally 250 mg twice daily (b.i.d.) and 500 mg once a day (q.d.). Blood and saliva samples were collected on study days 1 and 5 to determine the pharmacokinetics of clarithromycin and its 14-hydroxy metabolite in plasma and saliva, and to measure concentrations of… (More)

Topics

Cite this paper

@article{Kees1995SerumAC, title={Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.}, author={Frieder K Kees and Marina Wellenhofer and Horst F. Grobecker}, journal={Infection}, year={1995}, volume={23 3}, pages={168-72} }